BioGenerator’s largest investment in any single company is paying off for St. Louis. Confluence Life Sciences, Inc. has been acquired by Aclaris Therapeutics, Inc. for the St. Louis company’s world-class research team, intellectual property and drug discovery assets.
At Illumina, we’re committed to unlocking the power of the genome, and we know we can’t do it alone. Illumina Accelerator is our way of accelerating innovation in the entrepreneurial community. With extensive mentorship, financial support, and access to sequencing systems, reagents, and lab space, we are building a dynamic ecosystem to help genomics startups launch in the San Francisco Bay Area. Together, we’ll advance breakthrough applications in genomics, including therapeutics, diagnostics, agriculture, synthetic biology, forensics, and direct-to-consumer applications.
Join the Greater Baltimore Committee for its annual Economic Outlook Conference, which this year will focus on Washington uncertainties and what does it mean for Maryland’s economy. Hear from Paul Heckley, Health Economist and Leading Expert on U.S. Health Industry Trends and Reform, and Dean Zerbe, Former Senior Counsel to U.S. Senate Finance Committee, AlliantGroup National, Managing Director.
When: Thursday, September 14, 2017; 7:30 a.m. registration, 8 a.m. program
Where: Renaissance Baltimore Harborplace Hotel, 202 East Pratt Street, Baltimore, MD 21202
September 25th – 27th, 2017 – San Jose, California
The MedTech Conference is your opportunity to connect with thousands of medical technology professionals this September. Join us in San Jose for business development, innovative technology, and networking with policymakers, business executives and industry leaders.
Calling all medical device innovators! This year’s symposium will host the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) competition. Up to six innovations will be awarded up to $50,000 each during the “Make Your Medical Device Pitch for Kids!” competition.
At the John’s Hopkins Kimmel Cancer Center, researchers have been working for years to figure out how prostate cancer cells are able to move from one infected organ and spread to other parts of the body.
“Because we know that’s the type of cancer that eventually will kill a man with prostate cancer,” said Johns Hopkins Associate Professor of Oncology and Pathology. Dr. Srinivasan Yegnasubramanian.
AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, respectively. Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme, aiming to develop combination regimens that will deliver innovative medicines to patients.
It figures a personalized health accelerator would want to personalize the experience for its companies.
When Virginia health system Inova Health closed on the 117-acre former Exxon-Mobil campus in Fairfax back in 2015, it was clear there was plenty of space to do something bold. (It was called the real estate deal of the year.) And from the start personalized medicine was going to be the focus.
The company alleges the U.S. Food and Drug Administration isn’t honoring a drug designation program Congress passed in 1983.
You are invited to travel with County Executive Ike Leggett, MCEDC, other county officials and select area business leaders on an exclusive Business Development trip to South Korea and China, October 20-29, 2017. Our delegation will visit some of the most forward-thinking technology hubs and global commerce destinations of East Asia including Seoul, Daejeon, Xi’an and Shanghai.
